Sandbox vidit: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(52 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{{familytree/start}}
{{familytree/start}}
{{familytree | | | | | | | A01 | | | | | | | | | | |A01=[[Atrial flutter]] }}
{{familytree | | | | | | | | | | | | A01 |-| A02 |-| A03 | | | | |A01=<div style="float: left; text-align: left; padding:1em">'''Confirmed aortic dissection''' <br> ❑ Check whether dissection occurred in ascending aorta </div>|A02=Yes |A03=Consider surgical management}}
{{familytree | | | |,|-|-|-|^|-|-|-|.| | | | | | | | }}
{{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | |}}
{{familytree | | | B01 | | | | | | B02 | | | | | | |B01=Unstable |B02=Stable }}
{{familytree | | | | | | | | | | | | B01 | | | | | | | | | | | | |B01=No}}
{{familytree | | | |!| | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | |}}
{{familytree | | | C01 | | | | | | C02 | | | | | | |C01=<div style="float: left; text-align: left; width:25em; padding:1em;">❑ Look for the presence of any of these: <br>
{{familytree | | | | | | | | | | | | C01 | | | | | | | | | | | | |C01=<div style="float: left; text-align: left; padding:1em">❑ Start Medical management </div>}}
:❑ Chronic heart failure
{{familytree | | | | | | | | | | | | |!| | | | | | | | | | | | | |}}
:❑ Hypotension
{{familytree | | | | | | | | | | | | D01 | | | | | | | | | | | | |D01=<div style="float: left; text-align: left; padding:1em">❑ Check Vitals <br>
:❑ Acute myocardial infarction <br>
:Blood pressure in both arms <br>
</div>|C02=<div style="float: left; text-align: left; width:25em; padding:1em;"> ❑ Administer anticoagulation therapy based on the risk of stroke, if total duration of flutter > 48 hours <br> ❑ Administer rate control therapy (AV nodal blockers) <br><br> ''THEN'' <br><br>❑ Attempt conversion
:❑ Take the highest reading for treatment or goal therapy <br>
:❑ DC cardioversion
Is patient hemodynamically stable ?</div> }}
:Atrial pacing
{{familytree | | | | | | | | |,|-|-|-|^|-|-|-|-|-|-|-|.| | | | | |}}
:❑ Pharmacological cardioversion
{{familytree | | | | | | | | E01 | | | | | | | | | | E02 | | | | |E01=Yes |E02=No}}
</div> }}
{{familytree | | | | | | | | |!| | | | | | | |,|-|-|-|^|-|-|-|.| |}}
{{familytree | | | |`|-|-|-|v|-|-|-|'| | | | | | | | }}
{{familytree | | | | | | | | F01 | | | | | | F02 | | | | | | F03 |F01=<div style="float: left; text-align: left; padding:1em">❑ Control rate and pressure<br>
{{familytree | | | | | | | D01 | | | | | | | | | | |D01=<div style="float: left; text-align: left; width:25em; padding:1em;"> ❑ Assess need for therapy to prevent recurrence </div> |D02=}}
: ❑ I.V [[Beta blockers]] or [[labetalol]]
{{familytree | | | | | | | |!| | | | | | | | | | | | }}
: ❑ Substitute [[diltiazem]] and [[verapamil]]<br> If [[betablockers]] are contraindicated
{{familytree | | | | | | | E01 | | | | | | | | | | |E01=<div style="float: left; text-align: left; width:25em; padding:1em;"> ❑ Administer antiarrythmic therapy to prevent recurrences
----
----
❑ Consider catheter ablation if antiarrhythmic therapy fails </div>}}
❑ Goal Heart rate should be 60 beats per minute
----
❑ Pain control<br>
: ❑ Use [[Opiates]]</div> |F02=<div style="float: left; text-align: left; padding:1em"> ❑ '''Type A dissection'''
----
❑ Expedited surgical consultation and consider surgery (Urgent)<br>
❑ Maintain Euvolemic status<br>
: ❑ Intravenous fluid replacement<br>
:❑ Maintain [[mean arterial pressure|mean arterial pressure (MAP)]] of 70 mm of hg<br>
❑ Rule out complications using imaging study<br>
: ❑ [[Cardiac tamponade|Pericardial tamponade]]
: ❑ [[Aortic rupture|Rupture of aorta]]<br>
: ❑ [[Aortic insufficiency]]</div>|F03=<div style="float: left; text-align: left; padding:1em">❑ Type B dissection
----
❑ Intravenous fluid replacement<br>
: ❑ Maintain [[mean arterial pressure|mean arterial pressure (MAP)]] of 70 mm of hg<br>
❑ Start vasopressor if still hypotensive
----
❑ Find out etiology of hypertension
:❑ Imaging to find out contained rupture
:❑ Perform [[Echocardiography|Transthoracic echocardiogram (TTE)]] to assess cardiac function
----
❑ Consider surgical evaluation</div> }}
{{familytree | | | | | | | | |!| | | | | | | |!| | | | | | | |!| |}}
{{familytree | | | | | | | | |!| | | | | | | G01 | | | | | | |!| |G01=<div style="float: left; text-align: left; padding:1em">❑ Can the cause of hypotension respond to surgical management</div>}}
{{familytree | | | | | | | | |!| | | |,|-|-|-|^|-|-|-|.| | | |!| |}}
{{familytree | | | | | | | | H01 |-| H02 | | | | | | H03 |-| H04 |H01=<div style="float: left; text-align: left; padding:1em">❑ Monitor vitals closely
: ❑ Maintain systolic BP <120 mm of Hg</div> |H02=No |H03=Yes |H04=Consider surgical management}}
{{familytree | | | | |,|-|-|-|^|-|-|-|.| | | | | | | | | | | | | |}}
{{familytree | | | | I01 | | | | | | I02 | | | | | | | | | | | | |I01=Yes |I02=No}}
{{familytree | | | | |!| | | | | | | |!| | | | | | | | | | | | | |}}
{{familytree | | | | |!| | | | | | | J01 |-|-|-|-|-| J02 | | | | |J01=<div style="float: left; text-align: left; padding:1em"> ❑ Check whether dissection involves ascending aorta</div> |J02=Yes}}
{{familytree | | | | |!| | | | | | | |!| | | | | | | |!| | | | | |}}
{{familytree | | | | |!| | | | | | | K01 | | | | | | |!| | | | | |K01=No}}
{{familytree | | | | |!| | | | | | | |!| | | | | | | |!| | | | | |}}
{{familytree | | | | |`|-|-| L01 |-|-|'| | | | | | | |!| | | | | |L01=<div style="float: left; text-align: left; padding:1em">❑ Control blood pressure
: ❑ Intravenous vasodilator</div>}}
{{familytree | | | | | | | | |!| | | | | | | | | | | |!| | | | | |}}
{{familytree | | | | | | | | M01 | | | | | | | | | | |!| | | | | |M01=<div style="float: left; text-align: left; padding:1em">❑ Monitor vitals closely
: ❑ Maintain systolic BP <120 mm of Hg</div>}}
{{familytree | | | | | | | | |!| | | | | | | | | | | |!| | | | | |}}
{{familytree | | | | | | | | N01 |-| N02 |-| N03 |-|-|'| | | | | |N01=<div style="float: left; text-align: left; padding:1em">❑ Check for any complications which might require surgery
----
: ❑ Malperfusion
: ❑ Progressing dissection
: ❑ Expansion of aortic aneurysm
: ❑ [[Hypertension causes|Uncontrolled or refractory hypertension]] </div> |N02=Yes|N03=<div style="float: left; text-align: left; padding:1em">❑ Consider surgical management</div>}}
{{familytree | | | | | | | | |!| | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | O01 | | | | | | | | | | | | | | | | |O01=No}}
{{familytree | | | | | | | | |!| | | | | | | | | | | | | | | | | |}}
{{familytree | | | | | | | | P01 | | | | | | | | | | | | | | | | |P01=<div style="float: left; text-align: left; padding:1em">❑ Switch to oral medications <br>
:❑ [[Betablockers]]
:❑ Antihypertensive regimen
----
❑ Follow up in the outpatient</div>}}
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
 
==First Initial Rapid Evaluation of Suspected Aortic Dissection==
Shown below is an algorithm for the First Initial Rapid Evaluation (FIRE) of Aortic dissection.
{{familytree/start}}
{{familytree | | | | | | | | | | A01 | | | | | | | | | | |A01=❑ Identify cardinal signs and symptoms that increase the pretest probability of acute aortic rupture }}
{{familytree | | | | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | | B01 | | | | | | | | | | |B01=<div style="text-align: left">❑ Sudden onset chest pain (tearing/ripping/sharp or stabbing)<br>
❑ Asymmetric blood pressure in extremities<br>
❑ Shock <br>
❑ Pulse deficit <br>
❑ Evolving aortic regurgitation murmur </div>}}
{{familytree | | | | | | |,|-|-|-|^|-|-|-|.| | | | | | | | }}
{{familytree | | | | | | C01 | | | | | | C02 | | | | | | |C01=<div style=" background: #F60A0A"> {{fontcolor|#F8F8FF|Unstable patient}} </div>|C02=Stable patient }}
{{familytree | | | | | | |!| | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | D01 | | | | | | D02 | | | | | | |D01=<div style="background: #F60A0A; text-align: left"> {{fontcolor|#F8F8FF|❑ Order urgent TTE <br> ❑ Look for the following high risk features: <br>
:❑ Pericardial effusion <br>
:❑ Regional wall motion abnormality (RWMA) <br>
:❑ Dilated root <br>
:❑ Aortic regurgitation (AR)}} </div>  |D02=[[Aortic dissection resident survival guide#Diagnosis|Continue with diagnostic approach]] }}
{{familytree | | | | | | |!| | | | | | | | | | | | | | | | }}
{{familytree | | | | | | E01 | | | | | | | | | | | | | | |E01=<div style=" background: #F60A0A; text-align: left"> {{fontcolor|#F8F8FF|❑ Aortic dissection confirmed
❑ Transfer to Cardio-thoracic unit
❑ Perform TEE in CCU or cardiac OR }} </div>}}
{{familytree | | | | | | |!| | | | | | | | | | | | | | | | }}
{{familytree | | | | | | F01 | | | | | | | | | | | | | | |F01=<div style=" background: #F60A0A"> {{fontcolor|#F8F8FF|❑ Proceed to surgery}} </div> }}
{{familytree/end}}
{{familytree/end}}


==Anticoagulation Therapy==
Look for the following: Intimal flap and tear <br> Intimal entry <br> Mobile linear flap in short axis view <br> Small central true lumen communicating with false lumen
Shown below are tables depicting the assessment of risk of stroke and the appropriate anticoagulation therapy among patients with Atrial flutter.<ref name="Fuster-2011">{{Cite journal  | last1 = Fuster | first1 = V. | last2 = Rydén | first2 = LE. | last3 = Cannom | first3 = DS. | last4 = Crijns | first4 = HJ. | last5 = Curtis | first5 = AB. | last6 = Ellenbogen | first6 = KA. | last7 = Halperin | first7 = JL. | last8 = Kay | first8 = GN. | last9 = Le Huezey | first9 = JY. | title = 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. | journal = Circulation | volume = 123 | issue = 10 | pages = e269-367 | month = Mar | year = 2011 | doi = 10.1161/CIR.0b013e318214876d | PMID = 21382897 }}</ref>
 
{| style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center; colspan="2"| {{fontcolor|#FFF|Anticoagulation Therapy}}
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | '''''No risk factors''''' ||style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aspirin]] 81-325 mg daily'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |'''''1 Moderate risk factor''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Aspirin]] 81-325 mg daily''''' <br> ''OR'' <br> ▸ '''''[[Warfarin]] (INR 2.0 to 3.0, target 2.5)'''''
|-
|style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |'''''Any high risk factor or <br> more than 1 moderate risk factor''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Warfarin]] (INR 2.0 to 3.0, target 2.5)'''''
|-
|}
|}
<br>
 
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
|-
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Low Risk Factors'''|| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Moderate Risk Factors'''|| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''High Risk Factors'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Female gender'''''<BR>▸ '''''Age 65-74 years'''''<BR> ▸ '''''[[Coronary artery disease]]'''''<BR>▸ '''''[[Thyrotoxicosis]]'''''|| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Age ≥ 75 years'''''<BR>▸ '''''[[Hypertension]]'''''<BR> ▸ '''''[[Heart failure]]'''''<BR>▸ '''''LV [[ejection fraction]] ≤ 35%'''''<BR>▸ '''''[[Diabetes mellitus]]''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Previous [[stroke]], [[TIA]] or [[embolism]]'''''<BR>▸ '''''[[Mitral stenosis]]'''''<BR> ▸ '''''[[Prosthetic heart valve]]'''''
|-
|}
 
===Pharmacological cardioversion===
{| style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center; colspan="2"| {{fontcolor|#FFF|Pharmacological Cardioversion for Atrial Flutter}}
|-
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Drug''' || style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Dosage'''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Flecainide]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence A]]) ''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ ''''' Oral: 200 to 300 mg <br> ▸ Intravenous: 1.5 to 3.0 mg/kg, over 10 to 20 min'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ibutilide]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence A]]) ''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Intravenous: 1 mg over 10 min, repeat 1 mg if necessary'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Propafenone]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence A]]) ''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ ''''' Oral: 600 mg <br> ▸ Intravenous: 1.5 to 2.0 mg/kg, over 10 to 20 min'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] <br>([[ACC AHA guidelines classification scheme|class IIa, level of evidence A]])  ''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ ''''' Oral:'''''
: '''''Inpatient'''''<br>
:▸ '''''1.2 to 1.8 g per day in divided dose until a maximum of 10 g '''''<br>
:▸ '''''Followed by a maintenance dose of 200 to 400 mg per day or 30 mg/kg''''' <br>
: '''''Outpatient'''''
:▸ '''''600 to 800 mg per day divided dose until a maximum of 10 g'''''<br>
:▸ '''''Followed by a maintenance dose of 200 to 400 mg per day ''''' <br>
▸ '''''Intravenous:'''''
: '''''5 to 7 mg/kg, over 30 to 60 min''''' <br> '''''Followed by 1.2 to 1.8 g per day continuous IV''''' <br> ''OR''<br>
: '''''5 to 7 mg/kg, in divided oral doses until a maximum of 10 g <br> Followe by a maintenance dose of 200 to 400 mg per day'''''
|-
|}
|}
 
===Antiarrhythmic Therapy===
 
{| style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center; colspan="2"| {{fontcolor|#FFF|Maintenance of Sinus Rhythm}}
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (100 to 400 mg)'''''<BR>''OR''<BR>▸ '''''[[Disopyramide]] (400 to 750 mg)'''''<BR>''OR''<BR> ▸ '''''[[Dofetilide]] (500 to 1000 mcg)'''''<BR>''OR''<BR>▸ '''''[[Flecainide]] (200 to 300 mg)'''''<BR>''OR''<BR>▸ '''''[[Procainamide]] (1000 to 4000 mcg)'''''<BR>''OR''<BR>▸ '''''[[Propafenone]] (450 to 900 mg)'''''<BR>''OR''<BR>▸ '''''[[Quinidine]] (600 to 1500 mg)'''''<BR>''OR''<BR>▸ '''''[[Sotalol]] (160 to 320 mg)'''''
|-
|}
|}
 
==Heart Rate Control==
 
Shown below is a table summarizing the list of recommended agents for control of heart rate and their dosages.<ref name="Fuster-2011">{{Cite journal  | last1 = Fuster | first1 = V. | last2 = Rydén | first2 = LE. | last3 = Cannom | first3 = DS. | last4 = Crijns | first4 = HJ. | last5 = Curtis | first5 = AB. | last6 = Ellenbogen | first6 = KA. | last7 = Halperin | first7 = JL. | last8 = Kay | first8 = GN. | last9 = Le Huezey | first9 = JY. | title = 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. | journal = Circulation | volume = 123 | issue = 10 | pages = e269-367 | month = Mar | year = 2011 | doi = 10.1161/CIR.0b013e318214876d | PMID = 21382897 }}</ref>
 
{| style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center; colspan="3"| {{fontcolor|#FFF|Heart Rate Control in Acute Setting}}
|-
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Drug'''|| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Loading dose''' || style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Maintenance dose'''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Heart rate control in patients without [[accessory pathway]]'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Esmolol]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''500 mcg/kg IV over 1 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''60 to 200 mcg/kg/min IV'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Propanolol]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.15 mg/kg IV''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metoprolol]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''2.5 to 5 mg IV bolus over 2 min; up to 3 doses''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Diltiazem]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.25 mg/kg IV over 2 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''5 to 15 mg/h IV'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Verapamil]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.075 to 0.15 mg/kg IV over 2 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Heart rate control in patients with [[accessory pathway]]'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] <br>([[ACC AHA guidelines classification scheme|class IIa, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''150 mg over 10 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 to 1 mg/min IV'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Heart Rate Control in patients with [[heart failure]] and without [[accessory pathway]]'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Digoxin]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.25 mg IV each 2 h, up to 1.5 mg''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.125 to 0.375 mg daily IV or orally'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] <br>([[ACC AHA guidelines classification scheme|class IIa, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''150 mg over 10 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 to 1 mg/min IV'''''
|-
| style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center colspan="3"| {{fontcolor|#FFF|'''Heart Rate Control in Non Acute Setting and Long Term Maintenance'''}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Heart rate control'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metoprolol]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''25 to 100 mg twice a day, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''25 to 100 mg twice a day, orally'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Propanolol]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''80 to 240 mg daily in divided doses, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''80 to 240 mg daily in divided doses, orally'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Verapamil]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses, orally'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Diltiazem]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses, orally'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center; colspan="3" | '''''Heart Rate Control in patients with heart failure and without accessory pathway'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Digoxin]] <br>([[ACC AHA guidelines classification scheme|class I, level of evidence B]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 mg by mouth daily''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.125 to 0.375 mg daily, orally'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] <br>([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''800 mg daily for 1 week, orally <br> 600 mg daily for 1 week, orally <br> 400 mg daily for 4 to 6 week, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''200 mg daily, orally'''''
|-
|}
|}

Latest revision as of 22:25, 1 April 2014

First Initial Rapid Evaluation of Suspected Aortic Dissection

Shown below is an algorithm for the First Initial Rapid Evaluation (FIRE) of Aortic dissection.

 
 
 
 
 
 
 
 
 
 
 
Confirmed aortic dissection
❑ Check whether dissection occurred in ascending aorta
 
Yes
 
Consider surgical management
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Start Medical management
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Check Vitals
❑ Blood pressure in both arms
❑ Take the highest reading for treatment or goal therapy
❑ Is patient hemodynamically stable ?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Control rate and pressure
❑ I.V Beta blockers or labetalol
❑ Substitute diltiazem and verapamil
If betablockers are contraindicated

❑ Goal Heart rate should be 60 beats per minute


❑ Pain control

❑ Use Opiates
 
 
 
 
 
Type A dissection

❑ Expedited surgical consultation and consider surgery (Urgent)
❑ Maintain Euvolemic status

❑ Intravenous fluid replacement
❑ Maintain mean arterial pressure (MAP) of 70 mm of hg

❑ Rule out complications using imaging study

Pericardial tamponade
Rupture of aorta
Aortic insufficiency
 
 
 
 
 
❑ Type B dissection

❑ Intravenous fluid replacement

❑ Maintain mean arterial pressure (MAP) of 70 mm of hg

❑ Start vasopressor if still hypotensive


❑ Find out etiology of hypertension

❑ Imaging to find out contained rupture
❑ Perform Transthoracic echocardiogram (TTE) to assess cardiac function

❑ Consider surgical evaluation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Can the cause of hypotension respond to surgical management
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Monitor vitals closely
❑ Maintain systolic BP <120 mm of Hg
 
No
 
 
 
 
 
Yes
 
Consider surgical management
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Check whether dissection involves ascending aorta
 
 
 
 
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Control blood pressure
❑ Intravenous vasodilator
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Monitor vitals closely
❑ Maintain systolic BP <120 mm of Hg
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Check for any complications which might require surgery
❑ Malperfusion
❑ Progressing dissection
❑ Expansion of aortic aneurysm
Uncontrolled or refractory hypertension
 
Yes
 
❑ Consider surgical management
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Switch to oral medications
Betablockers
❑ Antihypertensive regimen

❑ Follow up in the outpatient
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Identify cardinal signs and symptoms that increase the pretest probability of acute aortic rupture
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Sudden onset chest pain (tearing/ripping/sharp or stabbing)

❑ Asymmetric blood pressure in extremities
❑ Shock
❑ Pulse deficit

❑ Evolving aortic regurgitation murmur
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unstable patient
 
 
 
 
 
Stable patient
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Order urgent TTE
❑ Look for the following high risk features:
❑ Pericardial effusion
❑ Regional wall motion abnormality (RWMA)
❑ Dilated root
❑ Aortic regurgitation (AR)
 
 
 
 
 
Continue with diagnostic approach
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Aortic dissection confirmed

❑ Transfer to Cardio-thoracic unit

❑ Perform TEE in CCU or cardiac OR
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Proceed to surgery
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Look for the following: Intimal flap and tear
Intimal entry
Mobile linear flap in short axis view
Small central true lumen communicating with false lumen